Primary liver cancer

1 paper1 finding

Humans1

Upstream

1

Metabolic dysfunction-associated steatotic liver disease

no changein humans1

1 study

Metabolic dysfunction-associated steatotic liver disease has no effect on primary liver cancer in humans.
Humansin individuals with chronic HBV infectionmedian follow-up: 13.7 years
Concurrent MASLD and Long-term Outcomes in HBV-infected Individuals: A Population-based Cohort Study
Biomedical and environmental sciences : BES20 Jul 2026

More on Metabolic dysfunction-associated steatotic liver disease

Trial sponsors

Boston Scientific
Company1 trialPhase 2212 people

Latest

4 in 12 months

British Journal of Cancer17 Sep

Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women's health initiative randomized trials

Randomised trial in peopleLiver cancer

Arquivos Brasileiros de Cirurgia Digestiva19 Aug

Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus

ReviewIndustry & policy

Frontiers in Pharmacology7 Aug

Beyond cardiovascular protection: a conceptual and translational review of the hepato-specific mechanisms of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)

Biomedical and Environmental Sciences6 Aug

Concurrent MASLD and Long-term Outcomes in HBV-infected Individuals: A Population-based Cohort Study

Cohort study of 120,913 peoplePopulations